Prostatype Genomics AB AI Stock Analysis
Want to see SE:PROGEN full AI Analyst Report?
Prostatype Genomics AB (PROGEN) AI Stock Analysis
Prostatype Genomics AB
(Nasdaq OMX AB:PROGEN)
Prostatype Genomics scores near the bottom of the range. The dominant issue is financial fragility: negligible revenue, negative gross profit, persistent multi-year losses and an equity base of roughly SEK 6.5 million against approximately SEK 21 million of annual cash burn, pointing to an urgent funding need and likely shareholder dilution. Technicals reinforce the caution, with the price well below all major moving averages and negative MACD momentum. Valuation provides no cushion given negative earnings and no dividend. Modest offsets — a debt-free balance sheet and reduced cash burn — keep the score slightly above the floor, but this remains a highly speculative, high-risk profile dependent on commercial adoption of its prostate cancer test and successful refinancing.
Prostatype Genomics AB (PROGEN) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 64.02M
- Dividend Yield
- ―
- Average Volume (3M)
- 7.59M
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- -0.38
- Revenue Growth
- 143.94%
- EPS Growth
- 70.95%
- Country
- Sweden
- Employees
- 7
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Prostatype Genomics AB Business Overview & Revenue Model
Company Description
Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Sc...
Prostatype Genomics AB Financial Statement Overview
Summary
Financials are extremely weak. Revenue is immaterial at roughly SEK 1.0 million TTM, gross profit is negative (about -SEK 27.8 million), and net losses of SEK 38–45 million have persisted for four consecutive years. Shareholders' equity has collapsed to about SEK 6.5 million against an annual cash burn of roughly SEK 21 million, implying only a few months of runway and a high probability of dilutive refinancing. The only meaningful positives are the absence of interest-bearing debt and a narrowing cash burn versus 2024, which prevents a bottom-of-scale score but does not offset severe going-concern risk.
Income Statement
5Very NegativeBalance Sheet
14Very NegativeCash Flow
6Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.01M | 594.00K | 199.00K | 1.36M | 683.00K | 10.00K |
| Gross Profit | -27.83M | -37.62M | 1.92M | 3.73M | 683.00K | 2.51M |
| EBITDA | -34.16M | -36.89M | -37.40M | -38.02M | -26.79M | -15.46M |
| Net Income | -37.90M | -44.50M | -41.05M | -41.44M | -29.09M | -15.63M |
Balance Sheet | ||||||
| Total Assets | 39.91M | 50.86M | 41.97M | 49.22M | 30.95M | 40.20M |
| Cash, Cash Equivalents and Short-Term Investments | 392.00K | 9.07M | 9.42M | 2.68M | 11.49M | 20.33M |
| Total Debt | 0 | 5.30M | 67.00K | 11.67M | 867.00K | 1.27M |
| Total Liabilities | 33.36M | 24.33M | 8.50M | 24.55M | 4.80M | 4.30M |
| Stockholders Equity | 6.55M | 26.53M | 33.47M | 24.67M | 26.15M | 35.91M |
Cash Flow | ||||||
| Free Cash Flow | -20.96M | -24.06M | -52.57M | -37.70M | -27.69M | -18.58M |
| Operating Cash Flow | -20.90M | -23.80M | -44.71M | -29.14M | -27.69M | -16.08M |
| Investing Cash Flow | -12.27M | -13.36M | -8.36M | -8.57M | 0 | -2.50M |
| Financing Cash Flow | 20.64M | 36.83M | 59.75M | 28.91M | 18.85M | 23.05M |
Prostatype Genomics AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PROGEN, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.11, and below the 200-day MA of 0.22, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 39.44 is Neutral, neither overbought nor oversold. The STOCH value of 33.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PROGEN.
Prostatype Genomics AB Peers Comparison
Overall Rating
SE:DVYSR66Neutral
SE:IMMNOV46Neutral
SE:BIOVIC.B41Neutral
SE:QLINEA41Neutral
SE:PROGEN39Underperform
SE:ACARIX30Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 66Neutral | SEK 1.05B | 40.99 | ― | ― | 4.49% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | SEK 139.62M | -0.43 | -215.44% | ― | 148.66% | 66.30% | |
| 41Neutral | SEK 86.64M | -1.21 | -75.51% | ― | 56.06% | 63.95% | |
| 41Neutral | SEK 215.07M | -1.31 | -48.10% | ― | 33.26% | 90.73% | |
| 39Underperform | SEK 64.02M | -0.17 | -229.18% | ― | 143.94% | 70.95% | |
| 30Underperform | SEK 191.04M | -4.84 | -96.06% | ― | 40.61% | 32.63% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:PROGEN | Prostatype Genomics AB | 0.09 | -0.13 | -58.80% | |
| SE:IMMNOV | Immunovia AB | 0.04 | -0.14 | -77.71% | |
| SE:QLINEA | Q-linea AB | 11.15 | -13.80 | -55.31% | |
| SE:ACARIX | Acarix AB | 0.16 | -0.14 | -47.19% | |
| SE:BIOVIC.B | Biovica International AB Class B | 0.30 | -0.27 | -47.18% | |
| SE:DVYSR | Devyser Diagnostics AB | 60.00 | -51.00 | -45.95% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 30, 2026
